Skip to main content
. 2020 Mar 6;12(3):608. doi: 10.3390/cancers12030608

Figure 1.

Figure 1

Cisplatin resistance of IGROV-CP20 cells requires ATP7B. (A) IGROV (green) and IGROV-CP20 (red) cells were treated with the indicated concentrations of cisplatin for 24 or 48 h and viability of the cells was then evaluated using the MTT assay. (B,F,I) Western blots (and corresponding density quantifications) show ATP7B (B), ATP7A (F), and CTR1 (I) protein levels in IGROV and IGROV-CP20 cells (n = 3 experiments; * p < 0.05, ** p < 0.01, t-test). (C,G,J) qRT-PCR shows ATP7B (C), ATP7A (G), and CTR1 (J) mRNA levels in IGROV and IGROV-CP20 cells (n = 3 experiments; * p < 0.05, t-test). (D) IGROV and IGROV-CP20 cells were labeled for ATP7B and Golgin-97. Graphs (right column) indicate higher levels of ATP7B signal in IGROV-CP20 cells respect to the parental line. (E) IGROV-CP20 cells were transfected with control (siControl) or ATP7B-specific siRNAs and incubated with 50 µM cisplatin. MTT assay show reduced tolerance to cisplatin in ATP7B-silenced cells (n = 3 experiments; ** p < 0.01, ANOVA). (H) IGROV-CP20 cells were transfected with control (siControl) or ATP7A-specific siRNAs and incubated with 50 µM cisplatin. MTT assay did not detect viability differences between control and ATP7A-silenced cells upon cisplatin treatment. Scale bar: 25 µm (D).